Eicosanoids and the liver

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 3-4, 2000, Pages 163-174

  Tolman, Keith G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase; Digestive tract; Eicosanoid; Leukotriene; Liver

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; ICOSANOID; LEUKOTRIENE; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

HEPATITIS; HUMAN; KIDNEY DISEASE; LIVER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; NONHUMAN; REVIEW;

ANIMALS; EICOSANOIDS; HUMANS; LIVER;

EID: 0034040995     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00070-8     Document Type: Review

References (89)

1. Decker K. Eicosanoids, signal molecules of liver cells. Semin Liv Dis. 5:1985;175.
2. Ramwell P.W., Shaw J.E. Biological significance of the prostaglandins. Recent Prog Horm Res. 26:1970;139.
3. Huber M, Keppler D. Eicosanoids and the liver. In: Popper H, Schaffner, editors. Progress in liver diseases, Volume 9. Philadelphia: Saunders, 1990. p. 117.
4. 2 in carbon tetrachloride-induced acute hepatic injury in the rat. Prostaglandins. 32:1986;439.
5. Araki H., Lefer A.M. Cytoprotective actions of prostacyclin during hypoxia in the isolated profused cat liver. Am J Physiol. 238:1980;H176.
6. Davis D.C., Potter W.Z., Jollow D.J., Mitchell J.R. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci. 14:1974;2099.
7. 1 on T-cell mediated cytotoxicity against isolated mouse liver cells. Gastroenterology. 94:1988;1024.
8. Tiegs G., Wendel A. Leukotriene mediated liver injury. Biochem Pharmacol. 37:1988;2569.
9. Hagmann W., Steffan A.M., Kirn A., Keppler D. Leukotrienes as mediators in frog virus 3-induced hepatitis in rats. Hepatology. 7:1987;732.
10. Sinclair S., Levy G. Eicosanoids and the liver. Ital J Gastroenterol. 22:1990;205.
11. Peltekian K.M., Makowka L., Williams R., Blendis L.M., Levy G.A. Prostaglandins in liver failure and transplantation regeneration, immunomodulation, and cytoprotection . Prostaglandins in liver transplantation research group. Liver Transpl Surg. 2:1996;171.
12. Quiroga J., Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther. 58:1993;67.
13. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog. J Biol Chem. 266:1991;12866.
14. Holtzman M.J., Turk J., Shornick L.P. Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells. J Biol Chem. 267:1992;21438.
15. Sirois J., Simmons D.L., Richards J.S. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat pre-ovulating follicles induction in vivo and in vitro . J Biol Chem. 267:1992;11586.
16. Goppelt-Streube M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzyme expression. Prostaglandins Leukot Essent Fatty Acids. 52:1995;213.
17. Higgs G.A., Vane J.R. Inhibition of cyclooxygenase and lipoxygenase. Br Med Bull. 39:1983;265.
18. Hagmann W., Kaiser I., Jakschik B.A. The sensitized liver represents a rich source of endogenous leukotrienes. Hepatology. 13:1991;482.
19. Piper P.J. Formations and actions of leukotrienes. Physiol Rev. 64:1984;744.
20. Capdevila J., Pramanik B., Napoli J.L., Manna S., Falck J.R. Arachidonic acid epoxidation epoxyeicosatrienoic acids are endogenous constituents of rat liver . Arch Biochem Biophys. 231:1984;511.
21. Fitzpatrick F.A., Murphy R.C. Cytochrome P450 metabolism of arachidonic acid formation and biological actions of 'epoxygenase'-derived eicosanoids . Pharmacol Rev. 40:1988;229.
22. Sacerdoti D., Bolognesi M., Gatta A., McGiff J.C., Oyekan A. CYP450-dependent epoxyeicosatrenoic acids (EETs) may participate in the pathophysiology of portal hypertension by differentially modulating portal and mesenteric arterial resistance in cirrhotic rats. Hepatology. 30:1999;A307.
23. Brouwer A., Barelds R.J., De Leeuw A.M., et al. Isolation and culture of Kupffer cells from human liver. Ultrastructure, endocytosis and prostaglandin synthesis. J Hepatol. 6:1988;36.
24. Birmelin M., Decker K. Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells. Eur J Biochem. 142:1984;219.
25. Aderem A.A., Cohen D.S., Wright S.D., Cohn Z.A. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J Exp Med. 164:1986;165.
26. Mieli-Vergani G., Civeira P., Vergani D. Immunology and the liver. Prieto J., Rodes J., Shafritz D.A. Hepatobiliary Diseases. 1992;95 Springer-Verlag, Berlin.
27. Tran-Thi T.A., Gfyuko K., Henninger H., Busse R., Decker K. Studies on synthesis and degradation of ecosanoids by rat hepatocytes in primary culture. J Hepatol. 5:1987;322.
28. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. Arachidonic acid metabolism. Annu Rev Biochem. 55:1986;69.
29. 4 . Adv Exp Med Biol. 276:1990;533.
30. Fitzsimmons B.J., Rokach J. Lipoxygenase inhibitors and leukotriene receptor antagnoists. Church M., Robinson C. Advances in eicosanoid research - eicosanoids in inflammatory conditions. 1988;147 MTP Press, Lancaster, UK.
31. Nagai H., Aoki M., Shimazawa T., Yakuo I., Koda A., Kasahara M. Effect of OKY-046 and ONO-3708 on liver injury in mice. Jpn J Pharmacol. 51:1989;191.
32. 2) in liver injury in mice. Prostaglandins. 38:1989;439.
33. Hagmann W., Denzlinger C., Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock. 14:1984;223.
34. Tiegs G., Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol. 37:1988;2569.
35. Titos E., Claria J., Bosch-Marce M., et al. Mechanisms of increased hepatic cysteinyl-leukotriene. Hepatology. 30:1999;A294.
36. Stachura J., Tarnawski A., Ivey K.J., et al. Prostaglandin protection of carbon tetrachloride induced liver cell necrosis in the rat. Gastroenterology. 81:1981;211.
37. Guarner F., Freemont-Smith M., Corzo J., Quiroga J., Rodriguez J.L., Prieto J. In vivo and in vitro effects of arachidonic acid products on liver cell integrity following carbon tetrachloride poisoning. Samuelsson B., Paoletti R., Ramwell P. Advances in prostaglandin, thromboxane and leukotriene research. 1983;75 Raven Press, New York.
38. Guarner F., Boughton-Smith N.K., Blackwell G.J., Moncada S. Reduction by prostacyclin of acetaminophen-induced toxicity in the mouse. Hepatology. 8:1988;248.
39. 2 favorable effects on liver injury . Gastroenterology. 102:1992;572.
40. Samuelsson B., Goldyne M., Granstrom E., Hamberg M., Hammarström S., Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 47:1978;997.
41. 2 and some drugs on an acute galactosamine induced liver damage in rat. Folia Histochem Cytochem (Krakow). 18:1980;311.
42. Caldwell-Kankel J.C., Currin R.T., Tanaka Y., Thurmon R.G., Lemasters J.J. Kupffer cell activation and endothelial cell damage after storage of rat livers effect of reperfusion . Hepatology. 13:1991;83.
43. Goto M., Kawano S., Yoshihara H., et al. Hepatic tissue oxygenation as a predictive indicator of ischemia-reperfusion liver injury. Hepatology. 15:1992;432.
44. Koo A., Komatsu H., Tao G., Inoue M., Guth P.H., Kaplowitz N. Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion evidence for a role for superoxide anion . Hepatology. 15:1992;507.
45. α production by Kupffer cells following hypoxia-reoxygenation. Hepatology. 14:1991;51A.
46. Sutto F., Brault A., Le Page R., Huet P.M. Evaluation of liver endothelial cell (LEC) function using hyaluronic acid (HA) elimination during short cold ischemia. Hepatology. 14:1991;51A.
47. 2 and thromboxane antagonist on liver ischemic injury. Eur Surg Res. 21:1989;213.
48. Mora N.P., Cienfuegos J.A., Bernaldo de Quirss L., et al. Successful liver allograft function after 24 h preservation cumulative effects of prostacyclin plus Verapamil . Transplant Proc. 19:1987;3932.
49. Iwata K., Shimazu M., Wakabayashi G., Ohshima A., Yoshida M., Kitajima M. Intraportal perfusion of prostaglandin E1 attenuates hepatic postischemic microcirculatory impairments in rats. J Gastroenterol Hepatol. 14:1999;634.
50. Arai M., Thurman R.G., Lemasters J.J. cAMP mediates protective pre-conditioning of sinusoidal endothelial cells against storage/reperfusion injury. Hepatology. 30:1999;A605.
51. 2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest. 80:1987;881.
52. Hagmann W., Steffan A.M., Kirn A., Keppler D. Leukotrienes as mediators in frog virus 3-induced hepatitis in rats. Hepatology. 7:1987;732.
53. Quiroga J. Bile Salts, bile flow and cholestasis. Prieto J., Rodes J., Shafritz D.A. Hepatobiliary diseases. 1999;201 Springer-Verlag, Berlin.
54. 1 in an experimental massive hepatic cell necrosis model. Hepatology. 7:1987;1184.
55. 2 inhibits TNF production by Kupffer cells and prevents endotoxin induced mortality in mice. Gastroenterology. 102:1992;A846.
56. 2. J Clin Lab Immunol. 48:1996;17.
57. Sinclair S.B., Greig P.D., Blendis L.M., et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest. 84:1989;1063.
58. 1) has no beneficial effect in patients with either severe or fulminant hepatitis B. Hepatology. 12:1990;875.
59. 1 infusion improves survival of patients with fulminant hepatic failure. Gastroenterology. 102:1992;A862.
60. 2) in the treatment of fulminant hepatic failure (FHF). Hepatology. 16:1992;88A.
61. 1. Liver Transpl Surg. 4:1998;424.
62. Laffi G., LaVilla G., Pinzani M., Gentilini P. Lipid-derived autocoids, and renal function in liver cirrhosis. Epstein M. Kidney and liver disease. 1996;307 Hanley and Belfus, Philadelphia.
63. 1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 77:1979;215.
64. Arroyo V., Gines P., Jimenez W., Rodes J. Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis, and treatment. McIntyre M., Benhamou J.P., Bircher J., Rizetto N., Rodes J. The kidney and liver disease. 1991;429 Oxford Medical Press, Oxford.
65. Huber M., Kastner S., Scholmerich J., Gerok W., Keppler D. Analysis of cysteinyl leukotrienes in human urine enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome . Eur J Clin Invest. 19:1989;53.
66. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol. 17:1993;220.
67. 2 in primary biliary cirrhosis. Hepatology. 30:1999;A1255.
68. Lauterburg B., Paumgartner G., Preisig R. Prostaglandin-induced choleresis in the rat. Experientia. 31:1975;1191.
69. 1 on canine hepatic blood flow. J Surg Res. 18:1975;391.
70. Beckh K., Kneip S., Arnold R. Direct regulation of bile secretion by prostaglandins in perfused rat liver. Hepatology. 19:1994;1208.
71. 2-induced inhibition of interleukin 2 production. J Immunol. 130:1983;1770.
72. Rappaport R.S., Dodge G.R. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 155:1982;943.
73. 1 acts on two distinct pathways of T-lymphocyte activation inhibition of interleukin 2 production and down-regulation of transferrin receptor expression . J Immunol. 135:1985;1172.
74. 1 analogs. Transplantation. 50:1990;834.
75. 1 analog Misoprostol in renal transplant recipients treated with cyclosporin and Prednisolone. New Engl J Med. 322:1990;1183.
76. Curtis L.D., Anwar N., Briggs J., et al. Misoprostol in renal transplantation. Transplant Proc. 25:1993;602.
77. Weir M.R., Li X.W., Gomolka D., Peppler R., O'Bryan-Tear C.G., Moran M. The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45622). Transplantation. 52:1991;1053.
78. 1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc 1993;25:2381.
79. Quiroga J., Colina I., Demetris A.J., Starzl T.E., Van Thiel D.H. Cause and timing of first allograft failure in liver transplantation. A study of 177 consecutive patients. Hepatology. 14:1991;1054.
80. McKeown C.M., Edwards V., Phillips M.J., Harvey P.R., Petrunka C.N., Strasburg S.M. Sinusoidal lining cell damage the critical injury in cold preservation of liver allografts in the rat . Transplantation. 46:1988;178.
81. 1 results in increased graft and patient survival. Transplant Proc. 21:1989;2385.
82. Skouteris G.G., Ord M.G., Stocken L. Regulation of the proliferation of primary rat hepatocytes by eicosanoids. J Cell Physiol. 135:1988;516.
83. 2) therapy of primary nonfunction following liver transplantation. Transplant Proc. 24:1992;1985.
84. 1 treatment in orthoptic liver transplantation recipients indications and outcome . Transplant Proc. 24:1992;2248.
85. Briegel J.L., Haller M., Zulke C., et al. Primary graft nonfunction following orthotopic liver transplantation treatment with prostacyclin . Transplant Proc. 24:1992;2693.
86. Grazi G.L., Mazziotti A., Jovine E., et al. Prostaglandin therapy in primary liver graft nonfunction after orthototic transplantation. Transplant Proc. 26:1994;3651.
87. 1 in liver transplantation. Transplant Sci. 4:(Suppl):1994;S1.
88. Hamamoto I., Takaya S., Todo S., et al. Can adenine nucleotides predict primary non-function of the liver human liver homograft? Transpl Int. 7:1994;89.
89. 1 in liver transplantation. Hepatology. 21:1995;366.